PURPLE BIOTECH LTD. PPBT

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived Nasdaq

Last close —
Market cap —
52-week range — - —

No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.

Valuation FY2025 figures against the last close

P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS—

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue —————$1.0M$1.0M$1.0M$100.0K—
SG&A ————$6.1M$6.0M$4.4M———
Operating income ——-$22.3M-$22.6M-$17.9M-$12.6M-$7.2M-$7.8M-$12.0M-$7.2M
Net income -$26.5M-$7.3M-$20.0M-$21.8M$18.5M$28.1M$5.4M$5.6M$12.9M$12.1M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets $17.6M$37.0M$44.3M$54.6M$70.2M$83.8M$14.7M$14.7M$14.2M$14.9M
Total equity $9.7M$32.9M$34.3M$47.1M$65.1M$79.8M$10.9M$11.0M$8.7M$13.4M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Stock-based compensation ————$1.0M$1.1M$657.0K———

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-031365.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -40M -20M 0 20M 40M Net income, FY2016: 12.1M Revenue, FY2017: 100K Net income, FY2017: 12.9M Revenue, FY2018: 1M Net income, FY2018: 5.6M Revenue, FY2019: 1M Net income, FY2019: 5.4M Revenue, FY2020: 1M Net income, FY2020: 28.1M Net income, FY2021: 18.5M Net income, FY2022: -21.8M Net income, FY2023: -20M Net income, FY2024: -7.3M Net income, FY2025: -26.5M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue — $100.0K $1.0M $1.0M $1.0M — — — — —
Gross profit — — — — — — — — — —
Net income $12.1M $12.9M $5.6M $5.4M $28.1M $18.5M -$21.8M -$20.0M -$7.3M -$26.5M

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
LLY ELI LILLY & Co $1.20T 55.5x 44.7%
JNJ JOHNSON & JOHNSON $635.76B 23.9x 6.0%
ABBV AbbVie Inc. $504.76B 121.0x 8.6%
MRK Merck & Co., Inc. $358.41B 20.0x 1.3%
ABT ABBOTT LABORATORIES $180.63B 27.9x 5.7%
PFE PFIZER INC $171.16B 22.1x -1.6%
VRTX VERTEX PHARMACEUTICALS INC / MA $132.80B 34.2x 8.9%
BMY BRISTOL MYERS SQUIBB CO $125.59B 17.8x -0.2%